Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1)

Lung Cancer

Volumn 98, Issue , 2016, Pages 69-75

  Shimoji, Masaki ^a   Shimizu, Shigeki ^b   Sato, Katsuaki ^a   Suda, Kenichi ^a   Kobayashi, Yoshihisa ^a   Tomizawa, Kenji ^a   Takemoto, Toshiki ^a   Mitsudomi, Tetsuya ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Adenocarcinoma; EMT; Lung cancer; PD L1; Prognostic factor

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; E1L3N ANTIBODY; KI 67 ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; UNCLASSIFIED DRUG; VIMENTIN; MESSENGER RNA; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STEM CELL; CANCER SURGERY; CANCER TISSUE; CELL PROLIFERATION; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HOSPITAL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LABELING INDEX; LUNG ADENOCARCINOMA; LUNG CANCER CELL LINE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NON SMALL CELL LUNG CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOLID TUMOR; SQUAMOUS CELL LUNG CARCINOMA; TISSUE MICROARRAY; ADENOCARCINOMA; CANCER GRADING; CANCER STAGING; GENETICS; KAPLAN MEIER METHOD; LUNG TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SQUAMOUS CELL CARCINOMA; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; B7-H1 ANTIGEN; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RNA, MESSENGER;

EID: 84975291030     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.04.021     Document Type: Article

References (24)

1. Okazaki T., Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int. Immunol. 2007, 19:813-824. 10.1093/intimm/dxm057.
2. Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.J., Topalian S.L., Hwu P., Drake C.G., Camacho L.H., Kauh J., Odunsi K., Pitot H.C., Hamid O., Bhatia S., Martins R., Eaton K., Chen S., Salay T.M., Alaparthy S., Grosso J.F., Korman A.J., Parker S.M., Agrawal S., Goldberg S.M., Pardoll D.M., Gupta A., Wigginton J.M. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 2012, 366:2455-2465. 10.1056/NEJMoa1200694.
3. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., Powderly J.D., Carvajal R.D., Sosman J.A., Atkins M.B., Leming P.D., Spigel D.R., Antonia S.J., Horn L., Drake C.G., Pardoll D.M., Chen L., Sharfman W.H., Anders R.A., Taube J.M., McMiller T.L., Xu H., Korman A.J., Jure-Kunkel M., Agrawal S., McDonald D., Kollia G.D., Gupta A., Wigginton J.M., Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N. Engl. J. Med. 2012, 366:2443-2454. 10.1056/NEJMoa1200690.
4. Chen Y.B., Mu C.Y., Huang J.A. Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study. Tumori 2012, 98:751-755. 10.1700/1217.13499.
5. Mu C.Y., Huang J.A., Chen Y., Chen C., Zhang X.G. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med. Oncol. 2011, 28:682-688. 10.1007/s12032-010-9515-2.
6. Velcheti V., Schalper K.A., Carvajal D.E., Anagnostou V.K., Syrigos K.N., Sznol M., Herbst R.S., Gettinger S.N., Chen L., Rimm D.L. Programmed death ligand-1 expression in non-small cell lung cancer. Lab. Invest. 2014, 94:107-116. 10.1038/labinvest.2013.130.
7. Yang C.Y., Lin M.W., Chang Y.L., Wu C.T., Yang P.C. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur. J. Cancer 2014, 50:1361-1369. 10.1016/j.ejca.2014.01.018.
8. Zhang Y., Wang L., Li Y., Pan Y., Wang R., Hu H., Li H., Luo X., Ye T., Sun Y., Chen H. Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. Onco. Targets Ther. 2014, 7:567-573. 10.2147/OTT.S59959.
9. Azuma K., Ota K., Kawahara A., Hattori S., Iwama E., Harada T., Matsumoto K., Takayama K., Takamori S., Kage M., Hoshino T., Nakanishi Y., Okamoto I. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann. Oncol. 2014, 25:1935-1940. 10.1093/annonc/mdu242.
10. Sato K., Suda L., Mizuuchi H., Kobayashi Y., Shimoji M., Tomizawa K., Takemoto T., Iwasaki T., Sakaguchi M., Mitsudomi T. Molecular biological features for histologic subtypes of lung adenocarcinoma based on the new IASLC/ATS/ERS classification (in Japanese). Med. J. Kinki. Univ. 2015, 40:47-54.
11. Travis W., Brambilla E., Burke A., Marx A., Nicholson A. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart 2015, International Agency for Research on Cancer (IARC), Lyon.
12. Sasaki H., Suzuki A., Shitara M., Hikosaka Y., Okuda K., Moriyama S., Yano M., Fujii Y. PD-L1 gene expression in Japanese lung cancer patients. Biomed. Rep. 2013, 1:93-96. 10.3892/br.2012.10.
13. Noda Y., Fujita N., Kobayashi G., Ito K., Horaguchi J., Hashimoto S., Koshita S., Ishii S., Kanno Y., Ogawa T., Masu K., Tsuchiya T., Oikawa M., Honda H., Sawai T., Uzuki M., Fujishima F. Prospective randomized controlled study comparing cell block method and conventional smear method for bile cytology. Dig. Endosc. 2013, 25:444-452. 10.1111/j.1443-1661.2012.01404.x.
14. McCarty K.S., Miller L.S., Cox E.B., Konrath J., McCarty K.S. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch. Pathol. Lab. Med. 1985, 109:716-721.
15. Boland J.M., Kwon E.D., Harrington S.M., Wampfler J.A., Tang H., Yang P., Aubry M.C. Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. Clin. Lung Cancer 2013, 14:157-163. 10.1016/j.cllc.2012.05.006.
16. Kim M.Y., Koh J., Kim S., Go H., Jeon Y.K., Chung D.H. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: comparison with tumor-infiltrating T cells and the status of oncogenic drivers. Lung Cancer 2015, 88:24-33. 10.1016/j.lungcan.2015.01.016.
17. Kerr K.M., Tsao M.S., Nicholson A.G., Yatabe Y., Wistuba I.I., Hirsch F.R., Committee I.P. Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art?. J. Thorac. Oncol. 2015, 10:985-989.
18. Muenst S., Schaerli A.R., Gao F., Daster S., Trella E., Droeser R.A., Muraro M.G., Zajac P., Zanetti R., Gillanders W.E., Weber W.P., Soysal S.D. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res. Treat. 2014, 146:15-24. 10.1007/s10549-014-2988-5.
19. Chen L., Gibbons D.L., Goswami S., Cortez M.A., Ahn Y.H., Byers L.A., Zhang X., Yi X., Dwyer D., Lin W., Diao L., Wang J., Roybal J.D., Patel M., Ungewiss C., Peng D., Antonia S., Mediavilla-Varela M., Robertson G., Jones S., Suraokar M., Welsh J.W., Erez B., Wistuba I.I., Chen L., Peng D., Wang S., Ullrich S.E., Heymach J.V., Kurie J.M., Qin F.X. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat. Commun. 2014, 5:5241. 10.1038/ncomms6241.
20. Lamouille S., Xu J., Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 2014, 15:178-196. 10.1038/nrm3758.
21. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., Brooks M., Reinhard F., Zhang C.C., Shipitsin M., Campbell L.L., Polyak K., Brisken C., Yang J., Weinberg R.A. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715. 10.1016/j.cell.2008.03.027.
22. Borghaei H., Paz-Ares L., Horn L., Spigel D.R., Steins M., Ready N.E., Chow L.Q., Vokes E.E., Felip E., Holgado E., Barlesi F., Kohlhaufl M., Arrieta O., Burgio M.A., Fayette J., Lena H., Poddubskaya E., Gerber D.E., Gettinger S.N., Rudin C.M., Rizvi N., Crino L., Blumenschein G.R., Antonia S.J., Dorange C., Harbison C.T., Graf Finckenstein F., Brahmer J.R. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 2015, 373:1627-1639. 10.1056/NEJMoa1507643.
23. Brahmer J., Reckamp K.L., Baas P., Crino L., Eberhardt W.E., Poddubskaya E., Antonia S., Pluzanski A., Vokes E.E., Holgado E., Waterhouse D., Ready N., Gainor J., Aren Frontera O., Havel L., Steins M., Garassino M.C., Aerts J.G., Domine M., Paz-Ares L., Reck M., Baudelet C., Harbison C.T., Lestini B., Spigel D.R. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 2015, 373:123-135. 10.1056/NEJMoa150462717.
24. Mao Y., Li W., Chen K., Xie Y., Liu Q., Yao M., Duan W., Zhou X., Liang R., Tao M. B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer. Oncotarget 2015, 6:3452-3461. 10.18632/oncotarget.3097.